Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Payers and Partnerships: The Top Three Reimbursement Questions for Biotech Companies

This article was originally published in RPM Report

Executive Summary

CEOs of smaller biotech companies are often on the road trying to raise money or look at licensing deals. The ability to answer key reimbursement questions gives them a competitive advantage over their counterparts.

You may also be interested in...



Medicare Bill Allows Changes To Part D Protected Classes, Via Rule-Making

The new statutory requirement that Medicare drug plans cover all drugs in protected drug classes includes a hint of possible flexibility for interested stakeholders - the designated groups could be expanded or subtracted, though only through a formal regulatory process

More Research, Little Action On Comparative Effectiveness In Medicare Bill

Despite hopes that research on the comparative effectiveness of health services could both improve health care quality and reduce spending, the creation of an expanded federal program remains stuck in the examination phase

Part D’s Six Protected Drug Classes May Ride Baucus Medicare Vehicle

A statutory requirement that Medicare Part D drug plans cover "all or substantially all" drugs in six classes stands a good chance of making it into the Senate Finance Committee's upcoming Medicare physician payment package

Related Content

Topics

UsernamePublicRestriction

Register

PS080429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel